Silica-Based Nanomaterials for Diabetes Mellitus Treatment.
Diogo MarinheiroFátima MartelBárbara J M Leite FerreiraAna Luísa Daniel-da-SilvaPublished in: Bioengineering (Basel, Switzerland) (2022)
Diabetes mellitus, a chronic metabolic disease with an alarming global prevalence, is associated with several serious health threats, including cardiovascular diseases. Current diabetes treatments have several limitations and disadvantages, creating the need for new effective formulations to combat this disease and its associated complications. This motivated the development of therapeutic strategies to overcome some of these limitations, such as low therapeutic drug bioavailability or poor compliance of patients with current therapeutic methodologies. Taking advantage of silica nanoparticle characteristics such as tuneable particle and pore size, surface chemistry and biocompatibility, silica-based nanocarriers have been developed with the potential to treat diabetes and regulate blood glucose concentration. This review discusses the main topics in the field, such as oral administration of insulin, glucose-responsive devices and innovative administration routes.
Keyphrases
- glycemic control
- blood glucose
- type diabetes
- cardiovascular disease
- weight loss
- insulin resistance
- risk factors
- healthcare
- cancer therapy
- public health
- drug delivery
- blood pressure
- emergency department
- human health
- skeletal muscle
- adipose tissue
- metabolic syndrome
- coronary artery disease
- cardiovascular events
- cardiovascular risk factors
- drug release
- replacement therapy
- adverse drug